Halim MS, Afridi R, Hasanreisoglu M, et al. - Researchers identified baseline features of individuals enlisted in the READ-3 study that would predict the response of macular edema to ranibizumab (RBZ) therapy at year 1. Based on pre-defined retreatment criteria, patients with diabetic macular edema were randomized to receive monthly intravitreal injections of RBZ (0.5 or 2.0 mg) for 6 consecutive injections followed by as-needed treatments. For this sub-study, 123 out of 152 individuals were analyzed. Patients with high central subfield thickness (> 570 μm) at baseline may not benefit from repeated intravitreal injections of anti-VEGF for edema resolution.